Bayern. Suchtmedizinische Grundversorgung - 23.10.2023 (09:00 Uhr) - 27.10.2023 (17:20 Uhr)
Veranstalter: Ärztekammer Bayern
https://www.blaek.de/fortbildung/fortbildungskalender?typ=0&id_kursnr=893351
Nordrhein. Suchtmedizinische Grundversorgung - 23.02.2024 (15:00 Uhr) - 09.10.2024 (16:30 Uhr)
Veranstalter: (Ärztliche Akademie)
https://www.akademie-nordrhein.de/kursangebot/detail/suchtmedizinische-grundversorgung-20831
Brandenburg. Suchtmedizinische Grundversorgung
20.10.2023 - 20.01.2024
https://www.laekb.de/aerztin-und-arzt/fortbildung/fortbildungsangebote/veranstaltungen-der-laekb/detail/suchtmedizinische-grundversorgung
Baden-Württemberg. Suchtmedizinische Grundversorgung – 2023/2024
Termin: 09. bis 13. Oktober 2023
Termin: 26. Februar bis 01. März 2024, Montag bis Freitag von 09.00 s.t. - 18.00 Uhr
Termin: 21. bis 25. Oktober 2024, Montag bis Freitag von 09.00 s.t. - 18.00 Uhr
https://www.aerztekammer-bw.de/suchtmedizin-kursweiterbildung-zur-erlangung-der-zusatzbezeichnung-suchtmedizinische-grundversorgung-gem-wbo-2020-d6e78eb80835e608
Berlin und Hannover. Suchtmedizinische Grundbversorgung
Modul 1, 21.–23.06.2024
Modul 2, 06.–08.09.2024
Hannover.
Modul 1, 07.–09.06.2024 green
Modul 2, 06.–08.09.2024
VeranstalterAIM – Arbeitsgemeinschaft Interdisziplinäre Medizin, Hannover
https://aim-suchtmedizin.de/home#einfuehrung
Typology of laws restricting access to methadone treatment in the United States: A latent class analysis.
Conway A, Krawczyk N, McGaffey F, Doyle S, Baaklini V, Marshall AD, Treloar C, Davis CS, Colledge-Frisby S, Grebely J, Cerdá M.
Int J Drug Policy. 2023 Aug 2;119:104141. doi: 10.1016/j.drugpo.2023.104141. Epub ahead of print. PMID: 37540917.
https://www.sciencedirect.com/science/article/pii/S0955395923001883
First-line opioid agonist treatment as prevention against assisting others in initiating injection drug use: A longitudinal cohort study of people who inject drugs in Vancouver, Canada.
Bouck Z, Tricco AC, Rosella LC, Banack HR, Fox MP, Platt RW, Milloy MJ, DeBeck K, Hayashi K, Werb D.
Drug Alcohol Depend Rep. 2023 May 25;7:100168. doi: 10.1016/j.dadr.2023.100168. PMID: 37397436; PMCID: PMC10311194.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311194/
Fentanyl-Associated Overdose Deaths Outside the Hospital.
Jeffery MM, Stevens M, D'Onofrio G, Melnick ER.
N Engl J Med. 2023 Jul 6;389(1):87-88. doi: 10.1056/NEJMc2304991. Epub 2023 Jun 21. PMID: 37342960; PMCID: PMC10388669.
https://www.nejm.org/doi/10.1056/NEJMc2304991
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia (LINC-II): an open-label, randomised controlled trial
Samet, Jeffrey H et al.
The Lancet HIV, Volume 10, Issue 9, e578 - e587
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(23)00143-1/fulltext
Changing dynamics of drug overdoses in the United Kingdom: An attempt to replicate the Jalal et al. findings of steady exponential growth.
Aziani A, Caulkins JP.
Int J Drug Policy. 2023 Aug 4;119:104146. doi: 10.1016/j.drugpo.2023.104146. Epub ahead of print. PMID: 37544103.
https://www.sciencedirect.com/science/article/pii/S0955395923001937
Implementierung eines Pretomanid-basierten Therapieregimes bei multiresistenter Tuberkulose
The implementation of a pretomanid-based treatment regime for multiresistant tuberculosis: a case series.
Joean O, Trauth J, Ahrenstorf G, Kuhns M, Friesen I, Picksak G, Welte T, Ringshausen FC: Dtsch Arztebl Int 2023; 120: 641–2. DOI: 10.3238/arztebl.m2023.0172
https://www.aerzteblatt.de/archiv/234061
Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis.
Artenie A, Stone J, Facente SN, Fraser H, Hecht J, Rhodes P, McFarland W, Wilson E, Hickman M, Vickerman P, Morris MD.
J Infect Dis. 2023 Sep 15;228(6):662-673. doi: 10.1093/infdis/jiad169. PMID: 37486337; PMCID: PMC10503949.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503949/
Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl.
Chambers LC, Hallowell BD, Zullo AR, et al.
JAMA Netw Open. 2023;6(9):e2334540. doi:10.1001/jamanetworkopen.2023.34540
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2809633
Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta‐analyses.
Lindson N, Theodoulou A, Ordóñez-Mena JM, Fanshawe TR, Sutton AJ, Livingstone-Banks J, Hajizadeh A, Zhu S, Aveyard P, Freeman SC, Agrawal S, Hartmann-Boyce J.
Cochrane Database of Systematic Reviews 2023, Issue 9. Art. No.: CD015226. DOI: 10.1002/14651858.CD015226.pub2. Accessed 24 September 2023.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495240/
Psychedelic drug MDMA moves closer to US approval following success in PTSD trial
Long-awaited trial data show drug is effective at treating post-traumatic stress disorder in a diversity of people. (Nature, 14.09.2023)
https://www.nature.com/articles/d41586-023-02886-x
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.
Mitchell, J.M., Ot’alora G., M., van der Kolk, B. et al.
Nat Med (2023). doi.org/10.1038/s41591-023-02565-4
https://www.nature.com/articles/s41591-023-02565-4
Effects of U.S. State Medical Cannabis Laws on Treatment of Chronic Noncancer Pain.
Emma E. McGinty, Kayla N. Tormohlen, Nicholas J. Seewald, et al.
Ann Intern Med. [Epub 4 July 2023]. doi:10.7326/M23-0053
Abstract
https://www.acpjournals.org/doi/10.7326/M23-0053
Workload, Usability, and Engagement with a Mobile App Supporting Video Observation of Methadone Take-Home Dosing: Usability Study.
Idrisov B, Hallgren KA, Michaels A, Soth S, Darnton J, Grekin P, Woolworth S, Saxon AJ, Tsui JI.
JMIR Hum Factors. 2023 Jul 13;10:e42654. doi: 10.2196/42654. PMID: 37440298; PMCID: PMC10375394.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375394/
Addiction nursing competencies: A comprehensive toolkit for the addictions nurse.
Wason, K., Potter, A., Alves, J., Loukas, V. L., Lastimoso, C., Sodder, S., ... & LaBelle, C. T. (2021). JONA: The Journal of Nursing Administration, 51(9), 424-429.
https://journals.lww.com/jonajournal/Fulltext/2021/09000/Addiction_Nursing_Competencies__A_Comprehensive.4.aspx
Sucht bei Männern – zentrale Ursachen, geschlechtssensible Hilfen und mehr Prävention Zusammenfassung Sucht ist die häufigste psychische Störung bei Männern. Etwa drei Viertel der Alkohol- und Drogenabhängigen sind Männer. Deshalb sind geschlechtsspezifische Ursachenforschung, Prävention und Behandlung von größter Wichtigkeit. Acht zentrale Ursachen sind zu benennen: (1) biologisch Risiken, (2) Rollenstereotype, (3) externalisierende und impulsive Persönlichkeitsfaktoren, (4) peer-Druck, (5) Angst, Depression und Selbstwertprobleme, (6) Stressreduktion, (7) Einsamkeitsprobleme und (8) Abhängigkeits-Autonomiekonflikt. In Bezug auf Prävention und Therapie wird ein stets um eine jungen- und männerspezifische Perspektive erweitertes Vorgehen empfohlen und mit Beispielen erläutert. Dazu zählen im deutschen Sprachbereich vor allem Programme wie „Männlichkeiten und Sucht“ des LWL (Münster) oder „VIKTOR – Hilfen für ältere alkoholabhängige Männer“ des DISuP (Köln). (Michael Klein in addiction.de, 19.09.2023) https://www.addiction.de/sucht-bei-maennern/
Parental substance use disorder and risk of intellectual disability in offspring in Sweden: a national register study
Khemiri, Lotfi et al. eClinicalMedicine,
Volume 63, 102170
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00347-4/fulltext
International Journal of Drug Policy - Volume 119 , September 2023
https://www.sciencedirect.com/journal/international-journal-of-drug-policy/vol/119/suppl/C
Rasantes Wachstum von Mega-Zeitschriften birgt Chancen und Risiken
Stanford/Rom – Der Anteil an Artikeln, die in sogenannten Mega-Zeitschriften publiziert werden, nimmt gemessen an der Gesamtzahl der Fachzeitschriften zu. Den rasanten Zuwachs konnten Forschende der Stanford University und der Università Cattolica del Sacro Cuore in Rom für alle Wissenschaften zeigen, vor allem aber für die Biomedizin (JAMA 2023, DOI: 10.1001/jama.2023.3212). (aerzteblatt.de, 24.08.2023)
https://www.aerzteblatt.de/nachrichten/145183/Rasantes-Wachstum-von-Mega-Zeitschriften-birgt-Chancen-und-Risiken
Schottland. MAT Service Standards- Leaflet for people in treatment (June 2023)
(sdf – Scottish Drugs Forum, Schottland, 2023)
https://www.matstandards.co.uk/s/MAT-Leaflet-People-Using-Services-SDF-June-2023V1.pdf
USA. Medications for Opioid Use Disorder — MOUD — and Adolescents
Treatment with drugs such as buprenorphine, methadone and naltrexone is deemed the gold standard for youth with opioid addictions. Why isn’t it used more often? (Discover Magazine, USA, 16.07.2023)
https://www.discovermagazine.com/health/medications-for-opioid-use-disorder-moud-and-adolescents
Estimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics.
Jawa R, Tin Y, Nall S, et al.
JAMA Netw Open. 2023;6(4):e237888. doi:10.1001/jamanetworkopen.2023.7888
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2803734
USA. Did ASAM Fight to Limit Federal Methadone Reform Bill?
The American Society for Addiction Medicine (ASAM) successfully fought to prevent expansion of methadone prescribing to a wide range of medical practitioners in a current federal reform bill, alleges a source familiar with the negotiations.
Limiting prescribing to the much smaller group of specialists represented by ASAM weakens the bill’s ability to promote widespread, equitable access to the life-saving medication and prevent overdose deaths.
The United States’ policy of restricting methadone access to clinics, also known as opioid treatment programs (OTPs), is a death sentence. It is a major reason so many are dying from overdose. (Filter, USA, 25.07.2023)
https://filtermag.org/asam-methadone-reform-bill
Only 1 in 5 U.S. adults with opioid use disorder received medications to treat it in 2021
NIH and CDC study finds telehealth associated with increased likelihood of receiving evidence-based standard of care.
In 2021, an estimated 2.5 million people aged 18 years or older in the U.S. had opioid use disorder in the past year, yet only 1 in 5 of them (22%) received medications to treat it, according to a new study. Some groups were substantially less likely to receive medication for opioid use disorder, including Black adults, women, those who were unemployed, and those in nonmetropolitan areas. (NIH-NIDA, USA, 07.08.2023)
https://nida.nih.gov/news-events/news-releases/2023/08/only-1-in-5-us-adults-with-opioid-use-disorder-received-medications-to-treat-it-in-2021
Patient-Centered Outcomes Associated With a Novel Office-Based Opioid Treatment Program in a District Health Department: Mixed Methods Pilot Study
Coles T, Chen H, Des Marais A, Sachdeva N, Bush C, Macon Harrison L, Guthrie S
JMIR Form Res 2023;7:e40897, doi: 10.2196/40897
https://formative.jmir.org/2023/1/e40897
USA. Einer von fünf Opioidabhängigen erhält medikamentöse Behandlung
Buford – Nur einer von fünf Erwachsenen mit Opioidabhängigkeit in den USA erhält eine medikamentöse Therapie dagegen. Das ist das Ergebnis einer kürzlich veröffentlichten Studie des National Institute on Drug Abuse (NIDA) und dem National Center for Injury Prevention and Control (Jama Network Open, 2023; DOI: 10.1001/jamanetworkopen.2023.27488). (aerzteblatt.de, 15.08.2023)
https://www.aerzteblatt.de/nachrichten/145072/Einer-von-fuenf-Opioidabhaengigen-erhaelt-medikamentoese-Behandlung
Seite 1 von 10